The Challenge of Finding a Cure for HIV Infection

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Science

• Publication date

  2009-03-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1126/science.1165706PMID 19265012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice

  2008cited by this paper
• Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.

  2008cited by this paper
• Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era

  2008cited by this paper
• Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

  2008cited by this paper
• Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

  2008cited by this paper
• Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

  2008cited by this paper
• HMBA Releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and Activates HIV Transcription

  2007cited by this paper
• Mesenchymal stem cells with high telomerase expression do not actively restore their chromosome arm specific telomere length pattern after exposure to ionizing radiation

  2007cited by this paper
• Cardiovascular risks of antiretroviral therapies.

  2007cited by this paper
• Insulin Resistance, Glucose Intolerance and Diabetes Mellitus in HIV-Infected Patients

  2007cited by this paper
• Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes

  2007cited by this paper
• Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.

  2007cited by this paper
• Regulation of HIV-1 latency by T-cell activation.

  2007cited by this paper
• CBF‐1 promotes transcriptional silencing during the establishment of HIV‐1 latency

  2007cited by this paper
• ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia

  2007cited by this paper
• Experimental approaches to the study of HIV-1 latency

  2007cited by this paper
• HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR

  2007cited by this paper
• c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter

  2007cited by this paper
• The survival benefits of AIDS treatment in the United States.

  2006cited by this paper
• Hexamethylbisacetamide Remodels the Human Immunodeficiency Virus Type 1 (HIV-1) Promoter and Induces Tat-Independent HIV-1 Expression but Blunts Cell Activation

  2006cited by this paper
• Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells

  2006cited by this paper
• Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1

  2006cited by this paper
• Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

  2006cited by this paper
• NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

  2006cited by this paper
• The cycle of human herpes simplex virus infection: virus transport and immune control.

  2006cited by this paper
• Controlling the elongation phase of transcription with P-TEFb.

  2006cited by this paper
• Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

  2006cited by this paper
• Molecular mechanisms of HIV-1 proviral latency

  2005cited by this paper
• Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy.

  2005cited by this paper
• Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

  2005cited by this paper
• IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

  2005cited by this paper
• Prostratin Antagonizes HIV Latency by Activating NF-κB*

  2004cited by this paper
• Prostratin antagonizes HIV latency by activating NF-kappaB.

  2004cited by this paper
• Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence

  2003cited by this paper
• Resting CD4+ T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus-Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy

  2003cited by this paper
• Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

  2002cited by this paper
• Prevalence and predictive value of intermittent viremia with combination hiv therapy.

  2001cited by this paper
• Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

  2001cited by this paper
• Residual HIV-RNA Levels Persist for Up to 2.5 Years in Peripheral Blood Mononuclear Cells of Patients on Potent Antiretroviral Therapy

  2000cited by this paper
• The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1

  2000cited by this paper
• Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

  1999cited by this paper
• Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

  1999cited by this paper
• Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy

  1999cited by this paper
• Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

  1999cited by this paper
• Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

  1999cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

  1997cited by this paper
• Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

  1997cited by this paper
• Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

  1988cited by this paper

• Traditional Medicine Extracts of Gnidia sericocephala and Product Nkabinde in HIV-1 Latency Reversal: Insights from J-Lat Subtype B and J-Lat Subtype C Models

  2026cites this paper
• Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection.

  2025cites this paper
• Mathematical modeling and mechanisms of HIV latency for personalized anti latency therapies

  2025cites this paper
• Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies

  2025cites this paper
• Vedolizumab: Beyond Inflammatory Bowel Disease

  2025cites this paper
• PKR Inhibitor C16 Regulates HIV-gp120 Induced Neuronal Injury and Cognitive Impairment in Vivo and in Vitro Models

  2025cites this paper
• Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

  2025cites this paper
• Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategies

  2025cites this paper
• Exploring evolutionary trajectories of drug resistance.

  2025cites this paper
• Novel bioinformatics approaches to design epitope-based vaccine against HIV latency by inquiring CTL epitopes and built-in adjuvants

  2025cites this paper
• A BRIEF OVERVIEW OF HIV TREATMENT STRATEGIES: A FOCUSED LOOK AT CHALLENGES AND OPPORTUNITIES

  2025influential citation
• HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data

  2025cites this paper
• Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review

  2025cites this paper
• HIV infection reprogrammes CD4+ T cells for quiescence and entry into proviral latency

  2025cites this paper
• Determination of Mineral Element Concentrations in Plasma Samples and Their Correlation to HIV/AIDS

  2025cites this paper
• Extracellular condensates (ECs) are endogenous modulators of HIV transcription and latency reactivation.

  2025cites this paper
• Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohorts

  2024cites this paper
• Inhibition of HIV-1 infection with curcumin conjugated PEG-citrate dendrimer; a new nano formulation

  2024cites this paper
• CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation

  2024cites this paper
• Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems

  2024cites this paper
• HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

  2024cites this paper
• Assessment of the toxicity of different antiretroviral drugs and their combinations on Sertoli and Leydig cells

  2024cites this paper
• Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  2024cites this paper
• Evaluation of HIV-1 DNA levels among adolescents living with perinatally acquired HIV-1 in Yaounde, Cameroon: A contribution to paediatric HIV cure research in Sub-Saharan Africa

  2024cites this paper
• Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies

  2024cites this paper
• Gesicles packaging dCas9-VPR ribonucleoprotein complexes can combine with vorinostat and promote HIV proviral transcription

  2024cites this paper
• Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques

  2024cites this paper
• Histone deacetylases and their inhibitors in inflammatory diseases.

  2024cites this paper
• High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells

  2024cites this paper
• Modeling virus-stimulated proliferation of CD4+ T-cell, cell-to-cell transmission and viral loss in HIV infection dynamics.

  2024cites this paper
• Machine learning approaches in designing anti-HIV nitroimidazoles: 2D/3D QSAR, kNN-MFA, docking, dynamics, PCA analysis and MMGBSA studies

  2024cites this paper
• Surface modification of graphene and fullerene with Sulfur (S), Selenium (Se), and Oxygen (O): DFT Simulation for enhanced zidovudine delivery in HIV treatment

  2024cites this paper
• Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy

  2024cites this paper
• Forging the tricyclic core framework of euphordraculoate B via a Barbier-type allyl addition.

  2024cites this paper
• Viral RNA capping: Mechanisms and antiviral therapy

  2024cites this paper
• HIV-1 latency reversal and immune enhancing activity of IL-15 is not influenced by sex hormones

  2024cites this paper
• Impact of misclassified defective proviruses on HIV reservoir measurements

  2023cites this paper
• HIV/AIDS Curability Study, Different Approaches and Drug Combination.

  2023cites this paper
• Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.

  2023cites this paper
• The Role of Plant Latex in Virus Biology

  2023cites this paper
• siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight

  2023cites this paper
• Scopoletin Reactivates Latent HIV-1 by Inducing NF-κB Expression without Global T Cell Activation

  2023cites this paper
• Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR

  2023cites this paper
• Suppressing Kaposi’s Sarcoma-Associated Herpesvirus Lytic Gene Expression and Replication by RNase P Ribozyme

  2023cites this paper
• A comprehensive overview on the role of phytocompounds in human immunodeficiency virus treatment.

  2023cites this paper
• HIV infection dynamics and viral rebound: Modeling results from humanized mice.

  2023cites this paper
• PolyIC-coated Prussian blue nanoparticles as a dual-mode HIV latency reversing agent.

  2023cites this paper
• Evaluation of Archival HIV DNA in Brain and Lymphoid Tissues

  2023cites this paper
• RNase P Ribozyme Effectively Inhibits Human CC-Chemokine Receptor 5 Expression and Human Immunodeficiency Virus 1 Infection

  2023cites this paper
• Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors

  2022cites this paper
• Dynamical Analysis of Posttreatment HIV‐1 Infection Model

  2022cites this paper
• Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication

  2022cites this paper
• Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal

  2022cites this paper
• Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics

  2022cites this paper
• Averting wildlife-borne infectious disease epidemics requires a focus on socio-ecological drivers and a redesign of the global food system

  2022cites this paper
• The nonequilibrium mechanism of noise-enhanced drug synergy in HIV latency reactivation

  2022cites this paper
• The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation

  2022cites this paper
• A Dynamic Interplay of Circulating Extracellular Vesicles and Galectin-1 Reprograms Viral Latency during HIV-1 Infection

  2022cites this paper
• Gene Editing via Integrase Enzyme

  2022cites this paper
• Epigenetic Landscape of HIV-1 Infection in Primary Human Macrophage

  2022cites this paper
• Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase

  2022cites this paper
• α4β7high CD4+ T cells are prone to be infected by HIV‐1 and associated with HIV‐1 disease progression

  2022cites this paper
• A functional map of HIV-host interactions in primary human T cells

  2022cites this paper
• Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPL’HIV Trial)

  2022cites this paper
• Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda

  2022cites this paper
• Epigenetic Landscape of HIV Infection in Primary Human Macrophage

  2022cites this paper
• Genotypic and Phenotypic Diversity of the Replication-Competent HIV Reservoir in Treated Patients

  2022cites this paper
• Polyphenol Extracts from Grape Seeds and Apple Can Reactivate Latent HIV-1 Transcription through Promoting P-TEFb Release from 7SK snRNP

  2022cites this paper
• Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring

  2022cites this paper
• The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription

  2022cites this paper
• ZBTB2 represses HIV-1 transcription and is regulated by HIV-1 Vpr and cellular DNA damage responses

  2021cites this paper
• Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption

  2021cites this paper
• A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

  2021cites this paper
• An in-depth analysis of novel combinatorial drug therapy via nanocarriers against HIV/AIDS infection and their clinical perspectives: a systematic review

  2021cites this paper
• HIV-1 Productively Infects and Integrates in Bronchial Epithelial Cells

  2021influential citation
• Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to antagonize HIV-1 latency.

  2021cites this paper
• Evaluation of HIV-1 Latency Reversal and Antibody-Dependent Viral Clearance by Quantification of Singly Spliced HIV-1 vpu/env mRNA

  2021cites this paper
• CARD8 is an inflammasome sensor for HIV-1 protease activity

  2021cites this paper
• Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents

  2021cites this paper
• An ultrasensitive planar array p24 Gag ELISA to detect HIV-1 in diverse biological matrixes

  2021cites this paper
• Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients

  2021cites this paper
• Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice

  2021cites this paper
• Emerging Single-cell Approaches to Understand HIV in the Central Nervous System

  2021cites this paper
• A realidade de idosos que vivem com AIDS no Brasil: uma revisão integrativa

  2021cites this paper
• An HIV-induced mechanism for T cell quiescence and proviral latency

  2021cites this paper
• Nanotechnology and Its Implication in Antiviral Drug Delivery

  2021cites this paper
• The HIV latency reversal agent HODHBt enhances NK Cell effector and memory-like functions by increasing IL-15 mediated-STAT activation

  2021cites this paper
• An ultrasensitive planar array p24 Gag ELISA to detect individual HIV-1 viral particles and infected cells

  2021cites this paper
• Metal-organic frameworks for diagnosis and therapy of infectious diseases

  2021influential citation
• Advanced baseline immunosuppression is associated with elevated levels of plasma markers of fungal translocation and inflammation in long-term treated HIV-infected Tanzanians

  2021cites this paper
• An Improved Tat/Rev Induced Limiting Dilution Assay With Enhanced Sensitivity and Breadth of Detection

  2021cites this paper
• MAT2A-Mediated S-Adenosylmethionine Level in CD4+ T Cells Regulates HIV-1 Latent Infection

  2021cites this paper
• Effect of Xanthium Strumarium on HIV-1 5′-LTR Transcriptional Activity and Viral Reactivation in Latently Infected Cells

  2021cites this paper
• A transient heritable memory regulates HIV reactivation from latency

  2021cites this paper
• Virus latency: Heterogeneity of host-virus interaction in shaping the virosphere

  2021cites this paper
• Combinatorial Use of Both Epigenetic and Non-Epigenetic Mechanisms to Efficiently Reactivate HIV Latency

  2021cites this paper
• Early-Transmitted Variants and Their Evolution in a HIV-1 Positive Couple: NGS and Phylogenetic Analyses

  2021cites this paper
• Anti-HIV Effects of Baculiferins Are Regulated by the Potential Target Protein DARS.

  2021cites this paper
• Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice

  2021cites this paper
• Large-scale allosteric switch in the 7SK RNA regulates transcription in response to growth and stress

  2021cites this paper